Clovis Oncology, Inc. reported consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported operating loss of $97.252 million against $41.120 million a year ago. Loss before income taxes was $99.273 million against $39.350 million a year ago. Net loss was $98.645 million or $2.62 per basic and diluted share against $39.642 million or $1.17 per basic and diluted share a year ago.

For the nine months, the company reported operating loss of $229.813 million against $104.569 million a year ago. Loss before income taxes was $233.828 million against $102.635 million a year ago. Net loss was $233.320 million or $6.62 per basic and diluted share against $105.124 million or $3.10 per basic and diluted share a year ago.

The company announced that Erle T. Mast, Executive Vice President & Chief Financial Officer of the company, has notified the company that he intends to retire March 31, 2016.